Insider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Sells 1,383 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Kymera Therapeutics Trading Up 3.3 %

KYMR stock opened at $31.70 on Thursday. The firm has a 50-day moving average price of $38.42 and a 200-day moving average price of $43.48. Kymera Therapeutics, Inc. has a 12 month low of $29.07 and a 12 month high of $53.27. The stock has a market capitalization of $2.06 billion, a P/E ratio of -13.55 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its position in Kymera Therapeutics by 3.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company’s stock valued at $276,395,000 after purchasing an additional 224,859 shares during the last quarter. Wellington Management Group LLP raised its holdings in Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after buying an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after buying an additional 650,000 shares during the period. FMR LLC grew its holdings in Kymera Therapeutics by 5.8% during the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after acquiring an additional 282,301 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Kymera Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock valued at $196,617,000 after acquiring an additional 133,546 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on KYMR shares. BMO Capital Markets began coverage on Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 target price for the company. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Stephens restated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Morgan Stanley lifted their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Finally, BTIG Research assumed coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.